Rare Disease Finance Insights Director

AstraZeneca; Dublin; On-site; EUR 125,000 - 150,000; Full time

Job summary

A leading pharmaceutical company in Dublin is seeking a qualified Group Insights Director to enhance decision-making through insightful financial analysis within their Rare Disease sector. Ideal candidates will possess significant finance qualifications (ACA/ACCA/CIMA/MBA), strong analytical and communication skills, and experience in commercial finance. The role requires building influential relationships and presenting to senior stakeholders, while driving performance through solid strategic planning. This position offers a chance to impact the organization significantly, with a deadline for applications on February 1, 2026.

Qualifications

• Experienced and analytical finance professional able to create high-impact materials for senior audiences.
• Proactive, delivery-focused, and energetic in a dynamic environment.
• Excellent in building relationships and engaging stakeholders.

Responsibilities

• Drive and shape AstraZeneca's commercial performance.
• Act as the authority for the Rare Disease business within Group Finance.
• Prepare strategic targets and manage key performance forecasts.

Skills

Analytical skills

Communication skills

Influencing skills

Networking

Education

Relevant Finance/Business qualification (e.g., ACA/ACCA/CIMA/MBA)

Excellent academic record

Tools

Microsoft Excel

PowerPoint

Hyperion Planning

Job description

A leading pharmaceutical company in Dublin is seeking a qualified Group Insights Director to enhance decision-making through insightful financial analysis within their Rare Disease sector. Ideal candidates will possess significant finance qualifications (ACA/ACCA/CIMA/MBA), strong analytical and communication skills, and experience in commercial finance. The role requires building influential relationships and presenting to senior stakeholders, while driving performance through solid strategic planning. This position offers a chance to impact the organization significantly, with a deadline for applications on February 1, 2026.